AI in Personalized Cancer Medicine: New Therapies Require Flexible and Safe Approval Conditions

The application of AI in precision oncology has so far been largely confined to the development of new drugs and had only limited impact on the personalisation of therapies. New AI-based approaches are increasingly being applied to the planning and implementation of personalised drug and cell therapies. Therapies can be adapted to individual patients' needs - for example to improve efficacy and dosage, reduce toxicity, develop combination therapies and even personalise preclinical cell therapies regarding their molecular properties.

AI-based healthcare is developing continuously and with increasing speed. It can support doctors with decision-making and therapy planning as well as in early multi-cancer precision diagnostics. Other potential applications include the design of new types of personalised medical products, drug companion apps for patients and the use of so-called "digital twins". The latter use patient data in almost real-time to enable more precise diagnosis by means of simulation and modelling and to adapt treatments to individual requirements. Advancing these products through regulatory pathways is enormously challenging. They combine technologies governed by different legal frameworks and regulatory bodies and are so novel that they are not well dealt with in current legislation. It can already be anticipated that the current approval conditions will make rapid clinical application difficult.

Making approval processes more agile in the future

The publication identifies two large challenges: legislators and regulatory bodies underestimate the importance of the developing technologies in this area as well as the extent of required regulatory change to make approval processes more agile in the future. "The current regulations are a de facto blocker to AI-based personalised medicine. A fundamental change is needed to solve this problem," says Stephen Gilbert, Professor of Medical Device Regulatory Science at the Else Kröner Fresenius Center for Digital Health at TU Dresden and University Hospital Carl Gustav Carus Dresden. The researchers therefore suggest, among other things, updating risk-benefit assessments for highly personalised treatment approaches. Solutions already established in the US could also be adopted in the EU for certain classes of low-risk decision support for doctors. The authors further suggest approaches to allow digital tools on market to be safety adaptable in a more flexible manner and to establish suitable test platforms for on-market monitoring. Multi-layered approaches would help to spread the load of oversight and make evaluation more relevant to patient safety.

Employees from the following institutions were involved in the publication: EKFZ for Digital Health at TU Dresden, University Hospital Carl Gustav Carus Dresden, Center for Scalable Data Analytics and Artificial Intelligence Dresden/Leipzig, Fraunhofer Institute for Cell Therapy and Immunology IZI (Leipzig), Institute for Clinical Immunology at University of Leipzig, University Clinic Marburg as well as the Université Paris-Saclay (Paris/France) and the life science consulting company ProductLifeGroup.

Bouchra Derraz, Gabriele Breda, Christoph Kaempf, Franziska Baenke, Fabienne Cotte, Kristin Reiche, Ulrike Köhl, Jakob Nikolas Kather, Deborah Eskenazy, Stephen Gilbert.
New regulatory thinking is needed for AI-based personalised drug and cell therapies in precision oncology.
npj Precision Oncology, 2024. doi: 10.1038/s41698-024-00517-w

Most Popular Now

Giving Doctors an AI-Powered Head Start …

Detection of melanoma and a range of other skin diseases will be faster and more accurate with a new artificial intelligence (AI) powered tool that analyses multiple imaging types simultaneously...

Philips Foundation 2024 Annual Report: E…

Marking its tenth anniversary, Philips Foundation released its 2024 Annual Report, highlighting a year in which the Philips Foundation helped provide access to quality healthcare for 46.5 million people around...

Scientists Argue for More FDA Oversight …

An agile, transparent, and ethics-driven oversight system is needed for the U.S. Food and Drug Administration (FDA) to balance innovation with patient safety when it comes to artificial intelligence-driven medical...

AI Agents for Oncology

Clinical decision-making in oncology is challenging and requires the analysis of various data types - from medical imaging and genetic information to patient records and treatment guidelines. To effectively support...

Start-ups in the Spotlight at MEDICA 202…

17 - 20 November 2025, Düsseldorf, Germany. MEDICA, the leading international trade fair and platform for healthcare innovations, will once again confirm its position as the world's number one hotspot for...

AI Medical Receptionist Modernizing Doct…

A virtual medical receptionist named "Cassie," developed through research at Texas A&M University, is transforming the way patients interact with health care providers. Cassie is a digital-human assistant created by Humanate...

Using Data and AI to Create Better Healt…

Academic medical centers could transform patient care by adopting principles from learning health systems principles, according to researchers from Weill Cornell Medicine and the University of California, San Diego. In...

AI Tool Set to Transform Characterisatio…

A multinational team of researchers, co-led by the Garvan Institute of Medical Research, has developed and tested a new AI tool to better characterise the diversity of individual cells within...

AI Detects Hidden Heart Disease Using Ex…

Mass General Brigham researchers have developed a new AI tool in collaboration with the United States Department of Veterans Affairs (VA) to probe through previously collected CT scans and identify...

Human-AI Collectives Make the Most Accur…

Diagnostic errors are among the most serious problems in everyday medical practice. AI systems - especially large language models (LLMs) like ChatGPT-4, Gemini, or Claude 3 - offer new ways...

Highland Marketing Announced as Official…

Highland Marketing has been named, for the second year running, the official communications partner for HETT Show 2025, the UK's leading digital health conference and exhibition. Taking place 7-8 October...

MHP-Net: A Revolutionary AI Model for Ac…

Liver cancer is the sixth most common cancer globally and a leading cause of cancer-related deaths. Accurate segmentation of liver tumors is a crucial step for the management of the...